verbio Vereinigte BioEnergie AG (DE:VBK)
XETRA:VBK
Want to see DE:VBK full AI Analyst Report?
Top Page
verbio Vereinigte BioEnergie
(XETRA:VBK)
Select Model
Select Model
Rating:55Neutral
Price Target:
€38.00
▲(7.04% Upside)
Action:ReiteratedDate:04/03/26
The score is held back primarily by weak current financial performance (losses and negative free cash flow) and an expensive valuation (very high P/E). These are partially offset by strong technical momentum and a more constructive earnings-call outlook, including improved EBITDA, positive Q2 free cash flow, and guidance tracking to the upper end of the prior range.
Positive Factors
Scale & diversified biofuel capacity
Verbio operates industrial-scale, multi-product facilities producing biodiesel, bioethanol and biomethane plus co-products. This asset and product diversification supports stable volume recovery, spreads operational risk across end markets and underpins resilient revenue streams as renewable fuel demand structurally grows.
Negative Factors
Weak profitability and negative margins
Persisting losses and compressed gross margins indicate structural pressure on earnings quality. Until the company sustains higher spreads or captures pricing gains from regulatory tailwinds, negative operating profitability will limit retained earnings, slow deleveraging and constrain long-term return generation.
Read all positive and negative factors
Positive Factors
Negative Factors
Scale & diversified biofuel capacity
Verbio operates industrial-scale, multi-product facilities producing biodiesel, bioethanol and biomethane plus co-products. This asset and product diversification supports stable volume recovery, spreads operational risk across end markets and underpins resilient revenue streams as renewable fuel demand structurally grows.
Read all positive factors
verbio Vereinigte BioEnergie (VBK) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€2.41B
Dividend Yield1.02%
Average Volume (3M)165.84K
Price to Earnings (P/E)106.0
Beta (1Y)0.71
Revenue Growth14.74%
EPS Growth-284.43%
CountryDE
Employees1,521
SectorGeneral
Sector StrengthN/A
IndustryChemicals - Specialty
Share Statistics
EPS (TTM)0.05
Shares Outstanding63,715,480
10 Day Avg. Volume196,028
30 Day Avg. Volume165,844
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.04
Price to Sales (P/S)0.49
P/FCF Ratio-6.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€33.50Price Target Upside-5.63% Downside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.52
Revenue Forecast (FY)€1.82B
verbio Vereinigte BioEnergie Business Overview & Revenue Model
Company Description
VERBIO Vereinigte BioEnergie AG produces and supplies biofuels in Germany and rest of Europe. The company's products include biodiesel, bioethanol, biomethane, biosterol, bioglycerin, and liquid fertilizers. The company offers its products to oil ...
How the Company Makes Money
Verbio primarily makes money by selling renewable fuels and related co-products produced at its plants. The core revenue stream is the sale of biofuels—most prominently biodiesel (from vegetable oils/fats) and bioethanol (typically from grain-base...
verbio Vereinigte BioEnergie Earnings Call Summary
Earnings Call Date:Feb 12, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:May 13, 2026
Earnings Call Sentiment Positive
The call conveyed a predominantly positive operational and financial momentum: strong EBITDA growth (QoQ and YoY), record European biodiesel production, higher ethanol/biomethane volumes, positive free cash flow in Q2, upgraded guidance to the upper end of the prior range, and constructive regulatory developments that should improve greenhouse-gas premium dynamics. Offsetting risks include seasonal/region-specific production curtailments (Canada), elevated CapEx and net debt during the investment phase, material-cost inflation, lingering regulatory uncertainty until legislation is finalized, and continued market volatility driven by weather and legacy fraud effects. Overall, the positives (clear earnings recovery, record volumes in Europe, strategic diversification and supportive regulatory trends) outweigh the negatives, though management remains cautious given remaining uncertainties.Positive Updates
Strong Group EBITDA Growth
Group EBITDA increased to EUR 30.1 million in Q2 (from EUR 20.8m in Q2 last year and EUR 15.4m in the previous quarter), representing approximately +44.7% year-over-year and +95.5% quarter-over-quarter growth.
Negative Updates
H1 Biodiesel Output Slightly Below Prior Year
Biodiesel output in the first half was 311,000 tonnes, slightly below the same period last year, driven largely by planned winter production curtailment in Canada and North American regulatory uncertainty.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Group EBITDA Growth
Group EBITDA increased to EUR 30.1 million in Q2 (from EUR 20.8m in Q2 last year and EUR 15.4m in the previous quarter), representing approximately +44.7% year-over-year and +95.5% quarter-over-quarter growth.
Read all positive updates
Company Guidance
Verbio said it now expects full‑year EBITDA to come in at the upper end of its prior guidance—previously described as a “high double‑digit euro million” range—while forecasting a moderate increase in free cash flow and a year‑on‑year reduction in net financial debt; in H1 the company reported an operating‑cash swing of EUR 21.7m to operating cash flow of EUR 35.6m, CapEx of EUR 47.8m, net debt of EUR 173m (down from a Q1 peak), an equity ratio of 58.2% and positive free cash flow in Q2, and Q2 group EBITDA was EUR 30.1m (vs. EUR 20.8m YoY and EUR 15.4m in Q1); management stressed CapEx remains tightly controlled, the ethanolysis plant in Bitterfeld is on track to produce first renewable molecules in H2‑2026, and noted they have taken a cautious stance on guidance until regulatory clarity (with any potential upward revision unlikely before end‑Q3).verbio Vereinigte BioEnergie Financial Statement Overview
Summary
Income Statement
28
Negative
Balance Sheet
56
Neutral
Cash Flow
34
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.72B | 1.58B | 1.67B | 1.97B | 1.81B | 1.03B |
| Gross Profit | 120.25M | 37.12M | 292.45M | 381.91M | 626.92M | 271.64M |
| EBITDA | 47.23M | -54.41M | 122.92M | 242.68M | 494.81M | 166.48M |
| Net Income | -112.18M | -138.01M | 19.96M | 132.02M | 315.63M | 93.20M |
Balance Sheet | ||||||
| Total Assets | 1.28B | 1.28B | 1.38B | 1.30B | 1.13B | 678.62M |
| Cash, Cash Equivalents and Short-Term Investments | 78.29M | 64.41M | 126.70M | 170.31M | 300.50M | 105.34M |
| Total Debt | 287.19M | 268.86M | 194.20M | 189.97M | 49.39M | 46.48M |
| Total Liabilities | 533.28M | 536.78M | 449.54M | 385.36M | 310.16M | 168.75M |
| Stockholders Equity | 742.75M | 746.29M | 925.67M | 909.47M | 816.23M | 507.85M |
Cash Flow | ||||||
| Free Cash Flow | -70.09M | -117.96M | -54.38M | -177.12M | 210.15M | 49.90M |
| Operating Cash Flow | 43.31M | 13.88M | 116.78M | 26.09M | 325.03M | 117.18M |
| Investing Cash Flow | -109.07M | -120.06M | -144.90M | -266.43M | -113.62M | -46.56M |
| Financing Cash Flow | 51.03M | 49.88M | -19.53M | 112.21M | -18.48M | -18.76M |
verbio Vereinigte BioEnergie Technical Analysis
Neutral
35.50
Price Trends
32.65
Positive
27.03
Positive
19.76
Positive
Market Momentum
1.31
Positive
45.57
Neutral
27.80
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:VBK, the sentiment is Neutral. The current price of 35.5 is below the 20-day moving average (MA) of 40.17, above the 50-day MA of 32.65, and above the 200-day MA of 19.76, indicating a neutral trend. The MACD of 1.31 indicates Positive momentum. The RSI at 45.57 is Neutral, neither overbought nor oversold. The STOCH value of 27.80 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for DE:VBK.
verbio Vereinigte BioEnergie Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | €4.91B | 16.33 | 16.02% | 3.91% | 1.08% | 1.74% | |
62 Neutral | €8.15B | 23.49 | 3.10% | 8.92% | -7.17% | 19.37% | |
57 Neutral | €4.51B | -4.20 | -19.52% | 3.75% | ― | ― | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | €2.41B | 106.00 | -14.46% | 1.02% | 14.74% | -284.43% | |
54 Neutral | €8.62B | 27.05 | 6.03% | 4.30% | -6.56% | -50.65% | |
49 Neutral | €1.54B | -2.64 | -14.66% | 0.59% | -10.89% | -225.99% |
* General Sector Average
DE:VBK
verbio Vereinigte BioEnergie
37.82
27.45
264.71%
DE:BNR
Brenntag AG
59.72
3.22
5.69%
DE:EVK
Evonik
17.50
-1.09
-5.89%
DE:FPE
Fuchs Petrolub
33.50
0.47
1.42%
DE:LXS
LANXESS
17.86
-8.32
-31.78%
DE:WCH
Wacker Chemie AG
90.70
25.86
39.88%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.